Privo Technologies

Privo Technologies Privo Technologies is a private company spun out of the world-renowned Langer Laboratory at MIT developing a novel new treatment platform for oral cancer.

Privo Technologies is a privately funded company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avo

ids stomach acids, can significantly reduce toxic side effects of drugs, and allows for higher dosing where the drugs can be most effective – all of which improve patient outcomes and compliance. Privo was founded by Manijeh Goldberg who is a seasoned executive with over 20 years experience in the medical industry as an executive leader and a scientist in large and small start-up companies, one of which (Epicon) was acquired for $275M. Her 12 years of large company experience includes working for HP medical and Siemens Medical Systems. Manijeh’s MBA from MIT and MS from Harvard Medical School led to her working with Professor Robert Langer. Professor Langer has global expertise in nanotechnology and drug delivery, and is now an advisor to Privo. Privo is focused on dramatically improving human health through its novel and proprietary Mucosal Delivery Particle (MDP) platform. Privo’s platform has both small and large molecule applications. The technologies used in Privo’s platform have previously received MIT’s prestigious Deshpande Center for Technological Innovation Award as well as an award from MIT’s 100k (Best Product) for work surrounding buccal delivery of insulin.

05/26/2025

🌟 Give Pets with Cancer a Second Chance

Every year, millions of dogs and cats are diagnosed with cancer.
Most families are faced with heartbreaking choices—and far too often, there’s no good option.
That’s why BeneVet Oncology exists.

We develop non-invasive cancer treatments for pets, giving them a chance to live longer, happier lives—without surgery or suffering.

We’ve already treated dogs and cats that no one else would help. Tumors too large. Cases too advanced.
And yet—they wagged their tails again. They played again. They got more time.

💔 1 in 4 dogs will die of cancer.
🙏 With your help, we can change that.

Your donation helps us treat real animals who still have love left to give.
🐶🐱 Every dollar goes toward compassionate-use therapies and expanding access.

📌 Click below to donate now and give pets another chance at life.
Together, we can fight for them.

[🔗 https://www.gofundme.com/f/support-benevet-lifesaving-cancer-treatments-for-pets]

Privo Technologies is a private company spun out of the world-renowned Langer Laboratory at MIT developing a novel new treatment platform for oral cancer.

We’re thrilled to announce the official launch of BeneVet Oncology ( subsidiary of PrivoTechnologies) — a bold new chapt...
05/23/2025

We’re thrilled to announce the official launch of BeneVet Oncology ( subsidiary of PrivoTechnologies) — a bold new chapter in advancing companion animal health through innovation. 🐶🐱
At Privo Technologies, we’ve always believed in transforming lives through science — and with BeneVet, we’re extending that mission to our four-legged family members. From cutting-edge treatments like PRV131 and PRV211 to compassionate care models, we’re bringing hope and healing to the veterinary world.
🔗 Read the full press release here:
https://www.bene-vet.com/

A huge thank you to our amazing team, partners, and the veterinary community. The future of oncology in pets just got brighter. ✨

Address

200 Corporate Place Suite 6B
Peabody, MA
01960

Alerts

Be the first to know and let us send you an email when Privo Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Privo Technologies:

Shortcuts

Share